Three doses of a live, oral bovine rotavirus pentavalent vaccine (BRV-PV) protected healthy infants in Niger from severe rotavirus gastroenteritis, reported a team of international investigators in the New England Journal of Medicine.
Rotavirus is a leading cause of diarrhea-associated hospitalization and death in children younger than 5 years around the world, with the highest death rate from this virus occurring in sub-Saharan Africa. Currently there are 2 licensed vaccines in use against rotavirus, but both require refrigeration. The BRV-PV vaccine, which was designed specifically for use in remote areas with limited electricity or health clinics, is freeze-dried, does not require refrigeration, and is thermostable for 2 years at 37°C and for 6 months at 40°C.
Friedrich M. Freeze-dried Rotavirus Vaccine Shows Promise. JAMA. 2017;317(19):1941. doi:10.1001/jama.2017.5482
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: